| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.65M | 54.47M | 50.04M | 42.20M | 39.04M | 29.69M |
| Gross Profit | 14.36M | 13.24M | 15.65M | 15.83M | 10.73M | 8.40M |
| EBITDA | 8.37M | 7.65M | 10.64M | 11.36M | 6.85M | 4.61M |
| Net Income | 4.82M | 2.92M | 6.56M | 7.87M | 9.19M | 1.28M |
Balance Sheet | ||||||
| Total Assets | 70.23M | 63.78M | 60.52M | 52.71M | 44.45M | 39.83M |
| Cash, Cash Equivalents and Short-Term Investments | 6.42M | 6.86M | 6.52M | 5.93M | 5.26M | 4.38M |
| Total Debt | 7.47M | 4.26M | 5.84M | 7.20M | 8.68M | 12.62M |
| Total Liabilities | 19.91M | 15.99M | 15.77M | 14.73M | 14.48M | 19.18M |
| Stockholders Equity | 50.32M | 47.79M | 44.75M | 37.97M | 29.96M | 20.66M |
Cash Flow | ||||||
| Free Cash Flow | -1.70M | 2.02M | 2.34M | 2.46M | 6.41M | 1.33M |
| Operating Cash Flow | 8.37M | 11.53M | 8.57M | 5.55M | 7.89M | 3.78M |
| Investing Cash Flow | -9.94M | -9.34M | -6.10M | -3.07M | -1.47M | -2.43M |
| Financing Cash Flow | 2.19M | -1.85M | -1.88M | -1.81M | -4.64M | -6.58M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | £45.09M | 12.11 | 10.25% | ― | 8.48% | 29.33% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | £214.18M | 304.86 | 0.60% | 1.73% | 15.56% | -92.94% | |
55 Neutral | £25.07M | -1.57 | ― | ― | -27.64% | 35.09% | |
53 Neutral | £6.31M | ― | -11.10% | ― | 14.51% | 77.27% | |
50 Neutral | £14.16M | -14.69 | -12.88% | ― | 25.56% | 35.12% | |
45 Neutral | £8.09M | -2.23 | -78.76% | ― | -24.85% | 40.28% |
Iofina plc reported a record quarter in iodine production, achieving a 32% year-on-year increase with 215.8 metric tonnes produced in Q3 2025. The company attributes this growth to the successful operation of its eight IOsorb® plants in Oklahoma, including the new IO#11 plant. With strong iodine prices and demand, Iofina is optimistic about meeting its production targets for the second half of the year and is in the final stages of negotiations for its IO#12 plant, indicating continued expansion and positive outlook into 2026.
The most recent analyst rating on (GB:IOF) stock is a Hold with a £25.00 price target. To see the full list of analyst forecasts on Iofina plc stock, see the GB:IOF Stock Forecast page.
Iofina plc reported record revenues and iodine production for the first half of 2025, with a 12.3% increase in revenue to $29.2 million and a 21.2% rise in gross profit to $6.3 million. The company achieved a 10.6% increase in iodine production, supported by strong market demand and high iodine prices. The commissioning of the new IO#11 plant is expected to significantly contribute to future production, with the company anticipating production of 400-440 metric tonnes of crystalline iodine in the second half of 2025. Iofina remains well-positioned to continue its growth strategy, leveraging strong cash generation and banking facilities to finance ongoing operational investments.
Iofina plc announced a record monthly iodine production of 74.3 metric tons in August 2025, attributed to efficient operations and the addition of a new plant, IO#11, to its portfolio. The company also reported a $1.8 million increase in cash reserves, thanks to Employee Retention Tax Credit refunds received for retaining employees during the COVID-19 pandemic. These developments underscore Iofina’s commitment to growth and operational efficiency, as it plans to expand into new areas and enhance future iodine production.